XBiotech Inc.

XBIT

XBiotech Inc.

XBIT

Insider Sentiment (TTM):

Last Purchase:2019-06-04Last Sale:2021-10-18Shares Purchased (TTM):0Shares Sold (TTM):0

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:1,992,538Shares Outstanding:30,487,731Institutional Ownership Pct.:6.54%

Earnings Market Reaction:

Filing Date:2026-08-13Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Cash And Cash Equivalents At Carrying Value	110	115	126	147	153	156	173	183	189	201	200	202
Short Term Investments	-	-	-	-	-	-	-	-	-	-	0	0
Accounts Receivable Net Current	-	-	-	0	0	0	-	1	1	1	-	1
Assets Current
Assets Current	111	117	127	149	155	158	175	185	191	203	202	204
Interest Receivable Current	0	0	0	-	-	-	1	-	-	-	1	-
Income Taxes Receivable	-	-	0	0	0	0	0	0	0	0	0	0
Prepaid Expense And Other Assets Current	1	1	1	1	1	1	1	1	1	1	1	1
Property Plant And Equipment Net	22	23	23	23	24	24	25	25	25	25	25	25
Assets	134	140	150	172	179	182	199	210	216	228	227	230
Accounts Payable Current	1	1	2	1	1	1	2	2	2	3	3	1
Accrued Liabilities Current	2	2	6	2	2	4	3	4	5	4	4	4
Liabilities Current
Liabilities Current	3	3	8	4	4	5	15	16	17	17	6	5
Accrued Income Taxes Current	0	0	0	0	0	0	0	0	0	0	0	0
Convertible Debt Current	-	-	-	-	-	-	-	10	10	10	-	-
Liabilities Noncurrent
Accrued Income Taxes Noncurrent	2	2	2	2	2	2	2	2	2	2	2	2
Deferred Income Tax Liabilities Net	0	0	0	-	-	-	0	-	-	-	0	0
Liabilities	5	5	10	5	6	7	17	18	19	19	8	7
Preferred Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Stockholders Equity
Common Stock Value	277	277	277	277	277	276	273	272	272	272	271	270
Stockholders Equity	128	135	140	167	173	175	182	192	197	209	219	223
Retained Earnings Accumulated Deficit	-149	-142	-136	-109	-103	-102	-91	-80	-75	-62	-52	-48
Accumulated Other Comprehensive Income Loss Net Of…	-	-	-	-	-	-	-	-	-	-	0	0
Liabilities And Stockholders Equity	134	140	150	172	179	182	199	210	216	228	227	230
Preferred Stock No Par Value	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Outstanding	-	-	-	0	0	0	0	0	0	0	0	0
Common Stock No Par Value	0	0	0	0	0	0	0	0	0	0	0	0
Shares Outstanding	30	30	30	30	30	30	30	30	30	30	30	30
Common Stock Shares Issued	30	30	30	30	-	-	30	-	-	-	30	30

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-5.20%	-8.00%	-10.40%	-	-	-	-	-	-	-	-	-
2025	0.69%	10.42%	-1.04%	-7.01%	-15.92%	-25.16%	-10.47%	-14.08%	-9.39%	1.73%	10.39%	4.76%
2024	-12.76%	-38.15%	-12.88%	-0.31%	14.37%	12.39%	-9.86%	-37.75%	-51.27%	-4.09%	-19.01%	-15.20%
2023	-	-	-	-	-	-	3.92%	4.44%	9.66%	38.92%	43.65%	22.67%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	33.15	39.03	16.01	41.78	40.16	29.15	11.56	11.57	11.13	12.03	33.07	38.61
Quick Ratio	32.75	38.60	15.88	41.48	39.82	28.93	11.49	11.51	11.06	11.96	32.94	38.44
Working Capital	107.81M	114.05M	119.02M	145.39M	151.03M	152.28M	159.46M	169.04M	173.50M	186.17M	195.62M	199.11M
Leverage & Debt
Debt to Equity	0.04	0.04	0.07	0.03	0.03	0.04	0.09	0.09	0.10	0.09	0.04	0.03
Interest Coverage TTM	-	-	-632.78	-118.77	-73.81	-64.99	-52.63	-70.17	-107.32	-206.09	-	-
Debt Ratio	0.04	0.03	0.06	0.03	0.03	0.04	0.08	0.08	0.09	0.08	0.03	0.03
Efficiency & Turnover
Asset Turnover TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding TTM	-	-	-	-	-	-	-	-	-	-	-	1,466.69
Receivables Turnover TTM	-	-	-	0.00	0.00	0.00	-	0.00	0.00	0.00	-	0.25
Per Share Metrics
Diluted EPS TTM	-	-	-1.49	-	-	-	-1.26	-	-	-	-0.81	-
Free Cash Flow Per Share TTM	-1.34	-1.39	-1.32	-0.78	-0.84	-1.04	-1.06	-0.96	-0.81	-0.71	-0.63	-0.62
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Operating Profit Margin TTM	-	-	-	-	-	-	-	-	-	-	-	-12,361.67%
Net Profit Margin TTM	-	-	-	-	-	-	-	-	-	-	-	-7,708.33%
Growth Metrics
Net Revenue Growth (1Y)	-	-	-	-	-	-	-	-100.00%	-100.00%	-100.00%	-100.00%	-96.35%
Net Income Growth (1Y)	60.26%	1.90%	18.19%	-10.72%	-19.55%	28.20%	56.90%	41.22%	23.18%	-1.85%	-25.36%	-36.06%
EPS Growth (1Y)	60.26%	1.90%	18.09%	-10.77%	-19.63%	28.02%	56.79%	41.06%	23.11%	-1.86%	-25.36%	-36.05%
Valuation Metrics
P/E TTM	-1.55	-1.78	-1.60	-2.78	-3.22	-2.51	-3.12	-7.21	-4.47	-8.05	-4.96	-5.42
P/B TTM	0.55	0.53	0.52	0.49	0.52	0.57	0.66	1.23	0.80	1.18	0.56	0.56
P/S TTM	-	-	-	-	-	-	-	-	-	-	-	418.00
Market Cap	70.12M	71.65M	72.87M	81.10M	90.55M	98.78M	120.32M	235.55M	156.54M	247.51M	121.75M	125.40M
Enterprise Value	-39.41M	-43.81M	-52.69M	-66.27M	-62.39M	-57.12M	-52.36M	62.43M	-21.99M	56.47M	-78.27M	-76.79M
Calculated Values
Free Cash Flow TTM	-40.84M	-42.36M	-40.21M	-23.85M	-25.66M	-31.62M	-32.27M	-29.19M	-24.53M	-21.73M	-19.09M	-18.84M
Net Debt	-109.53M	-115.46M	-125.55M	-147.37M	-152.94M	-155.90M	-172.68M	-173.12M	-178.53M	-191.04M	-200.02M	-202.19M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
PEG Ratio
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
EV Revenue TTM
EV FCF TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2021-10-18Sale

Owner: Simard, John

Title: Chief Executive Officer

Shares: 33,000

Price/Share: $13.07

Value: $431,310.00

Shares Owned: 3,823,166

Relationship: Director,Officer,TenPercentOwner

Ownership: Direct

2021-10-14Sale

Owner: Simard, John

Title: Chief Executive Officer

Shares: 21,125

Price/Share: $12.90

Value: $272,512.50

Shares Owned: 3,873,166

Relationship: Director,Officer,TenPercentOwner

Ownership: Direct

2021-10-06Sale

Owner: Simard, John

Title: Chief Executive Officer

Shares: 10,714

Price/Share: $12.53

Value: $134,246.42

Shares Owned: 3,962,452

Relationship: Director,Officer,TenPercentOwner

Ownership: Direct

2021-10-01Sale

Owner: Simard, John

Title: Chief Executive Officer

Shares: 19,684

Price/Share: $13.23

Value: $260,419.32

Shares Owned: 4,011,065

Relationship: Director,Officer,TenPercentOwner

Ownership: Direct

2021-09-27Sale

Owner: Simard, John

Title: Chief Executive Officer

Shares: 29,890

Price/Share: $14.81

Value: $442,670.90

Shares Owned: 4,071,966

Relationship: Director,Officer,TenPercentOwner

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2021-10-18	Simard, John	Director,Officer,TenPercentOwner	Chief Executive Officer	Direct	Sale	33,000	13.07	$431,310.00	3,823,166	4
2021-10-14	Simard, John	Director,Officer,TenPercentOwner	Chief Executive Officer	Direct	Sale	21,125	12.90	$272,512.50	3,873,166	4
2021-10-06	Simard, John	Director,Officer,TenPercentOwner	Chief Executive Officer	Direct	Sale	10,714	12.53	$134,246.42	3,962,452	4
2021-10-01	Simard, John	Director,Officer,TenPercentOwner	Chief Executive Officer	Direct	Sale	19,684	13.23	$260,419.32	4,011,065	4
2021-09-27	Simard, John	Director,Officer,TenPercentOwner	Chief Executive Officer	Direct	Sale	29,890	14.81	$442,670.90	4,071,966	4
2021-09-22	Simard, John	Director,Officer,TenPercentOwner	Chief Executive Officer	Direct	Sale	19,669	15.14	$297,788.66	4,123,166	4
2021-07-14	Simard, John	Director,Officer,TenPercentOwner	Chief Executive Officer	Direct	Sale	50,000	18.15	$907,500.00	4,173,166	4
2020-12-18	Bay, Street Financial S.A…	TenPercentOwner	-	Direct	Sale	1,173,033	18.78	$22,029,559.74	1,981,515	4
2020-12-02	Bay, Street Financial S.A…	TenPercentOwner	-	Direct	Sale	182,836	18.42	$3,367,839.12	3,154,548	4
2020-11-19	Mckenzie, W Thorpe	Director,TenPercentOwner	-	Direct	Sale	375,000	18.30	$6,862,500.00	2,560,964	4
2020-09-15	Shivaswamy, Sushma	Officer	Chief Scientific Officer	Direct	Sale	20,668	20.00	$413,360.00	0	4
2020-08-24	Han, Queena	Officer	VP Finance & HR	Direct	Sale	51,841	19.65	$1,018,675.65	0	4
2020-08-17	Han, Queena	Officer	VP Finance & HR	Direct	Sale	1,300	19.30	$25,090.00	0	4
2020-02-19	Bay, Street Financial S.A…	TenPercentOwner	-	Direct	Sale	1,662,616	6.38	$10,607,490.08	3,337,384	4
2019-09-06	Mckenzie, W Thorpe	Director,TenPercentOwner	-	Direct	Sale	7,159	3.69	$26,416.71	3,880,421	4
2019-06-04	Rennes, Fondation	TenPercentOwner	-	Direct	Purchase	1,200,000	8.25	$9,900,000.00	5,110,282	4
2019-03-04	Rennes, Fondation	TenPercentOwner	-	Direct	Purchase	16,426	7.91	$129,929.66	3,910,282	4
2019-03-01	Rennes, Fondation	TenPercentOwner	-	Direct	Purchase	34,999	8.13	$284,541.87	3,893,856	4
2019-02-07	Shivaswamy, Sushma	Officer	Chief Scientific Officer	Direct	Sale	4,500	10.00	$45,000.00	0	4
2019-02-07	Rennes, Fondation	TenPercentOwner	-	Direct	Purchase	40,000	10.00	$400,000.00	3,698,282	4
2018-12-27	Mckenzie, W Thorpe	Director,TenPercentOwner	-	Indirect	Purchase	1,364	4.92	$6,710.88	47,738	4/A
2018-12-24	Mckenzie, W Thorpe	Director,TenPercentOwner	-	Indirect	Purchase	24,838	5.88	$146,047.44	27,738	4
2018-11-12	Mckenzie, W Thorpe	Director,TenPercentOwner	-	Indirect	Purchase	700	3.75	$2,625.00	2,900	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

6.54%

Inst. Shares: 1,992,538

Shares Outstanding: 30,487,731

2025-12-31

7.53%

Inst. Shares: 2,295,081

Shares Outstanding: 30,487,731

2025-09-30

9.54%

Inst. Shares: 2,908,985

Shares Outstanding: 30,487,731

2025-06-30

11.20%

Inst. Shares: 3,414,475

Shares Outstanding: 30,487,731

2025-03-31

14.61%

Inst. Shares: 4,454,973

Shares Outstanding: 30,487,731

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	1,992,538	30,487,731	6.54%
2025-12-31	2,295,081	30,487,731	7.53%
2025-09-30	2,908,985	30,487,731	9.54%
2025-06-30	3,414,475	30,487,731	11.20%
2025-03-31	4,454,973	30,487,731	14.61%
2024-12-31	4,669,092	30,460,980	15.33%
2024-09-30	4,799,155	30,472,557	15.75%
2024-06-30	4,462,971	30,456,101	14.65%
2024-03-31	3,926,850	30,443,973	12.90%
2023-12-31	3,428,656	30,438,459	11.26%
2023-09-30	3,362,200	30,436,638	11.05%
2023-06-30	3,420,749	30,439,118	11.24%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

XBiotech Inc. (XBIT) — SEC Financial Statements & Analysis

XBiotech Inc. (XBIT) is a pharmaceutical preparations company, incorporated in A1. XBiotech Inc. trades on Nasdaq as: XBIT. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), XBiotech Inc. reported a -100.00% year-over-year revenue growth, a Debt-to-Equity ratio of 0.04x, a Price-to-Sales (P/S) ratio of 418.00x (TTM), a Price-to-Book (P/B) ratio of 0.55x (TTM), at a market cap of $70.12M. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: -100.00%
Debt To Equity: 0.04x
P/S TTM: 418.00x
P/B TTM: 0.55x
Market Cap: $70.12M

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is XBiotech Inc. in?

XBiotech Inc. (XBIT) operates in the Pharmaceutical Preparations industry.

What is XBIT's market cap?

XBiotech Inc. (XBIT) has a market capitalization of $70.12M as of 2026-06-30.

What exchange does XBIT trade on?

XBiotech Inc. (XBIT) trades on the Nasdaq.

Where is XBiotech Inc. incorporated?

XBiotech Inc. is incorporated in British Columbia, Canada.

XBiotech Inc.

Financial Statements

Custom Table

Interactive Financial Visualizations

Earnings Market Reaction

Performance and Valuation Metrics

Insider Transactions

Institutional Ownership

XBiotech Inc. (XBIT) — SEC Financial Statements & Analysis

Frequently Asked Questions

Companies in Pharmaceutical Preparations

Wall Street's data.
Main Street's price.

XBiotech Inc. (XBIT) — SEC Financial Statements & Analysis

Frequently Asked Questions

Companies in Pharmaceutical Preparations

Wall Street's data.Main Street's price.

Wall Street's data.
Main Street's price.